Expansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026SOUTH SAN FRANCISCO, Calif., April ...

Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call ...

NANJING, China, April 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully ...

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head ...

Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyy ...